FierceBiotech· @FierceBiotech · X·· 13 天前精选AI 评分58
AI 导读
诺和诺德在计提22亿美元减值费用、拖累季度利润后,仍计划通过收购填补其管线缺口。相关报道链接为 https://www.fiercebiotech.com/biotech/novos-ceo-still-looking-deals-close-some-gaps-misfires-hit-profits。
推荐理由
诺和诺德在计提22亿美元减值拖累季度利润后仍计划通过收购补管线缺口,读者可据此观察其BD策略走向。
正文
After $2.2 billion in impairment charges weighed on quarterly profits, Novo Nordisk is still looking to acquisitions to fill gaps in its pipeline. https://www.fiercebiotech.com/biotech/novos-ceo-still-looking-deals-close-some-gaps-misfires-hit-profits $NVO
来源:FierceBiotech · x.com